Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Was a Winner Today

By Eric Volkman - Updated Mar 30, 2021 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company won crucial regulatory approval in a massive new market.

What happened

Shares of Amarin (AMRN 5.15%) closed 3.9% higher on Tuesday, after there was some good news from across the Atlantic Ocean regarding the only product the company has on the market.

So what

That drug, Vascepa, is used to reduce the risk of stroke and heart attacks in patients taking statins for cardiovascular conditions. On Tuesday, the European Commission (EC), the executive branch of the European Union, approved the medication, which is sold under the brand name Vazkepa in that market.

Medical professionals talking in a hospital or clinic lobby.

Image source: Getty Images.

According to Amarin's announcement, this allows Vazkepa to be used "to reduce the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides ... and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor."

Vascepa, initially approved by the Food and Drug Administration in 2012, has faced challenges in the U.S. market. Last March, Amarin suffered a stinging defeat in a patent infringement lawsuit against generic drugmakers Hikma Pharmaceuticals and Dr. Reddy's Laboratories.

But Amarin will start off in a better position in Europe. As the biotech's chief scientific officer Steven Ketchum was quoted as saying, Vazkepa "offers the first and only EC-approved therapy to reduce cardiovascular risk in high-risk statin-treated patients who have elevated triglycerides." 

Now what

According to Amarin, cardiovascular disease is the top cause of death in the European Union. The EC's approval was expected (hence the modest pop in share price) given the drug's successful history in the U.S. Nevertheless, it opens a vast new market and loads the company with potential.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
$1.43 (5.15%) $0.07
Dr. Reddy's Laboratories Limited Stock Quote
Dr. Reddy's Laboratories Limited
$55.27 (-0.36%) $0.20
Hikma Pharmaceuticals PLC Stock Quote
Hikma Pharmaceuticals PLC
$42.54 (1.29%) $0.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.